CHRISTIANA BARDON

Christiana Bardon stands as a prominent figure in the biotechnology venture capital landscape, serving as a Managing Partner at MPM Capital. MPM Capital is renowned for its pioneering approach to investing in and building companies dedicated to developing transformative therapies for serious diseases. As a key leader within the firm, Dr. Bardon plays a crucial role in identifying and nurturing the next generation of life science innovations.

A significant aspect of her leadership at MPM Capital includes co-founding and co-managing the Oncology Impact Fund (OIF). This specialized fund is dedicated to investing in companies that are at the forefront of cancer research and treatment, aiming to accelerate the development of novel oncology therapies. Beyond oncology, Dr. Bardon's investment focus extends to other high-impact therapeutic areas, including rare diseases and conditions with significant unmet medical needs. She is deeply committed to supporting companies that leverage cutting-edge science to address critical health challenges and deliver meaningful patient outcomes.

Dr. Bardon's distinguished career background provides her with a unique perspective that blends deep scientific understanding with astute financial acumen. She holds an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School, a powerful combination that underpins her ability to evaluate complex scientific propositions through a rigorous business lens. Prior to her tenure at MPM Capital, Dr. Bardon honed her expertise as a healthcare analyst and portfolio manager at several leading investment firms, including Fidelity, SG Cowen, and Leerink Swann. This extensive experience in both public and private equity markets within the life sciences sector has equipped her with a comprehensive understanding of the entire drug development lifecycle and market dynamics.

Her investment strategy at MPM Capital is characterized by a commitment to fostering groundbreaking science. She actively seeks out companies with robust scientific platforms, innovative drug discovery approaches, and strong management teams capable of executing ambitious development plans. Whether through company creation, where MPM helps build new ventures from inception, or by investing in promising early-stage and growth-stage companies, Dr. Bardon is instrumental in guiding these enterprises toward clinical and commercial success. Her work directly contributes to advancing therapeutic development across various modalities, from small molecules and biologics to gene therapies, always with an eye toward therapies that can truly make a difference in patients' lives.

Through her leadership at MPM Capital and her strategic investments, Christiana Bardon continues to be a driving force in healthcare innovation. Her dedication to translating scientific breakthroughs into tangible medical solutions underscores her mission to improve global health outcomes, particularly in areas like oncology where the need for new treatments remains urgent. Her contributions are vital in shaping the future of biotechnology and bringing hope to patients worldwide.